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blocking dopamine D2 receptors, whereas acute clozapine
exerts its disruptive effect primarily by blocking the 5-HT2A
receptors. The repeated haloperidol effect may be mediated
by 5-HT2A/2C blockade-initiated neural processes, whereas
the repeated clozapine and olanzapine effect may be mediated by D2/3 blockade-initiated neural processes.

Abstract
Rationale — Acute antipsychotic treatment disrupts conditioned avoidance responding, and repeated treatment induces a sensitization- or tolerance-like effect. However, the
neurochemical mechanisms underlying both acute and repeated antipsychotic effects remain to be determined.
Objective — The present study examined the neuroreceptor
mechanisms of haloperidol, clozapine, and olanzapine effect
in a rat two-way conditioned avoidance model.
Methods — Well-trained Sprague–Dawley rats were administered with haloperidol (0.05 mg/kg, sc), clozapine (10.0 mg/
kg, sc), or olanzapine (1.0 mg/kg, sc) together with either saline, quinpirole (a selective dopamine D2/3 agonist, 1.0 mg/
kg, sc), or 2,5-dimethoxy-4-iodo-amphetamine (DOI; a selective 5-HT2A/2C agonist, 2.5 mg/kg, sc), and their conditioned
avoidance responses were tested over 3 days. After 2 days
of drug-free retraining, the repeated treatment effect was assessed in a challenge test.
Results — Pretreatment of quinpirole, but not DOI, attenuated
the acute haloperidol-induced disruption of avoidance responding and to a lesser extent, olanzapine-induced disruption. In contrast, pretreatment of DOI, but not quinpirole, attenuated the acute effect of clozapine. On the repeated effect,
pretreatment of DOI, but not quinpirole, attenuated the potentiated disruption of haloperidol, whereas pretreatment of
quinpirole attenuated the potentiated disruption of olanzapine but enhanced the tolerance-like effect of clozapine.
Conclusions — These findings suggest that acute haloperidol
and olanzapine disrupt avoidance responding primarily by

Keywords: Haloperidol, Clozapine, Olanzapine, Quinpirole,
2,5-dimethoxy-4-iodo-amphetamine, Repeated antipsychotic
treatment, Conditioned avoidance response, Sensitization,
Tolerance

Introduction
The conditioned avoidance response model (CAR)
is a fear-motivated instrumental conditioning model
which is traditionally used in behavioral pharmacology as a preclinical screen for antipsychotic activity
(Bolles 1970; Levis and Brewer 2001; Rescorla and Solomon 1967). In this model, acute treatment of antipsychotic drugs selectively disrupts avoidance responding without altering unconditioned escape response
(Arnt 1982; Wadenberg et al. 2001b). Recently, we have
expanded the use of this model to identify the behavioral mechanisms of action of antipsychotic drugs (Li
et al. 2007; Li et al. 2009a,b; Mead and Li 2009) and to
examine the anxiolytic property of atypical antipsy45
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chotic drugs (Mead et al. 2008). It is suggested that understanding the nature of the avoidance deficit induced
by antipsychotics may shed light on how antipsychotic
drugs achieve their clinical efficacy in the treatment of
psychosis (Li et al. 2009b).
Although the avoidance disruptive effect of antipsychotic treatment is robust and well-documented, the
neuroreceptor basis of this action is less clear. It has
also not been determined whether typical and atypical antipsychotics differ in their neurochemical mechanisms in this model (Wadenberg and Hicks 1999).
For typical antipsychotics such as haloperidol (HAL),
it is generally assumed (but not proven) that they disrupt avoidance behavior by blocking dopamine D2 receptors because they are primarily dopamine D2 antagonists (Dragunow et al. 1990; Seeman et al. 1976). In
contrast, atypical antipsychotics (e.g., clozapine, olanzapine) have multiple-receptor binding sites (Meltzer
et al. 1989; Miyamoto et al. 2005), making it more difficult to pinpoint their exact neurochemical mechanisms
relevant to their CAR effects. Both clozapine (CLZ) and
olanzapine (OLZ) possess a much more potent antagonism on the 5-HT2A/2C receptor in addition to relatively weak antagonism on D2 receptor (Meltzer et al.
2003). It is thus possible that their disruptive effect on
CAR could be attributed to their action on D2 receptor alone (Kapur and Seeman 2001; Wadenberg et al.
2001b) or its dual action on both 5-HT2A/2C and D2 receptor (Meltzer et al. 1989) or even effects on other receptors (e.g. D1, D4, 5-HT1A).
In the present study, we took a pharmacological approach to delineate the neuroreceptor mechanisms of
HAL, CLZ, and OLZ in a two-way CAR model. We examined how the avoidance disruptive effect of these
drugs was affected by pretreatments of quinpirole
(QUI), a selective D2/D3 dopaminergic receptor agonist
and/or 2,5-dimethoxy-4-iodo-amphetamine (DOI), a selective 5-HT2A/2C serotonergic receptor agonist. We recently applied a similar approach in a rat maternal behavior model and found that pretreatment of QUI, but
not DOI, dose-dependently reversed the HAL-induced
disruptions on active maternal responses, whereas pretreatment of DOI, but not QUI, dose-dependently reversed the CLZ-induced disruptions (Zhao and Li 2009).
Based on these findings and the receptor binding profiles of each antipsychotic (Miyamoto et al. 2005), we hypothesized that QUI, but not DOI, is able to attenuate
the HAL-induced disruption on CAR and may also be
effective in alleviating the OLZ-induced disruption to
some extent. In contrast, DOI, but not QUI, is able to attenuate the CLZ-induced disruption on CAR and may
also be effective in alleviating the OLZ-induced disruption to some extent. One additional experiment addressed the specificity of the reversal effects of QUI and
DOI on avoidance responding and its relation to their
psychomotor stimulating effects.
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In our previous studies (Li et al. 2007, 2009a,b; Mead
and Li 2009), we found that repeated antipsychotic treatment can produce a long-term change in its disruptive
effect on avoidance responding. For example, rats previously treated with HAL and OLZ made significantly
less avoidances than those who were treated with these
drugs for the first time (Mead and Li 2009). This finding
indicates that repeated antipsychotic treatment may induce a sensitization-like effect. However, we know almost nothing about the neuroreceptor mechanisms underlying this repeated drug effect in the avoidance
conditioning model. In the present study, we also examined how this long-term repeated effect was affected by
pretreatments of QUI and DOI to potentially elucidate
its mechanisms.
Materials and methods
Animals
Male Sprague–Dawley rats (226–250 g upon arrival, Charles River, Portage, MI) were housed two per
cage, in 48.3 × 26.7 × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions (light on between 6:30 a.m. and 6:30 p.m.). Room temperature was
maintained at 22 ± 1° with a relative humidity of 55–
60%. Food and water were available ad libitum. Animals were allowed at least 1 week of habituation to
the animal facility before being used in experiments.
All procedures were approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.

Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med Associates (St. Albans, VT) were used. Each box was housed
in a ventilated, sound-insulated isolation cubicle
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was
64 cm long, 30 cm high (from grid floor), and 24 cm
wide, and was divided into two equal-sized compartments by a partition with an arch style doorway (15 cm
high × 9 cm wide at base). A barrier (4 cm high) was
placed between the two compartments, so the rats had
to jump from one compartment to the other. The grid
floor consisted of 40 stainless-steel rods with a diameter
of 0.48 cm, spaced 1.6 cm apart center to center, through
which a scrambled footshock (US, 0.8 mA, maximum
duration: 5 s) was delivered by a constant current shock
generator (Model ENV-410B) and scrambler (Model
ENV-412). The rat location, motor activity (photobeam
breaks), and crossings between compartments were
monitored by a set of 16 photobeams (ENV-256-8P) af-
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fixed at the bottom of the box (3.5 cm above the grid
floor). Illumination was provided by two houselights
mounted at the top of each compartment. The CS (i.e.,
76 dB white noise) was produced by a speaker (ENV
224 AMX) mounted on the ceiling of the cubicle, centered above the shuttle box. Background noise (approximately 74 dB) was provided by a ventilation fan affixed
at the top corner of each isolation cubicle. All training
and testing procedures were controlled by Med Associates programs running on a computer.
Drugs
The injection solution of HAL (5.0 mg/ml ampoules, Shanghai Xudong Haipu Pharmaceutical Co.,
Ltd., Shanghai, China) was obtained by mixing drugs
with sterile water. CLZ and OLZ (gifts from NIMH
drug supply program) were dissolved in 1.0% glacial acetic acid in distilled water. QUI and DOI (RBISigma, Natick, MA) were dissolved in 0.9% saline.
All drugs were administered subcutaneously in a volume of 1.0 ml/kg body weight. Choices of drug doses
for HAL, CLZ, and OLZ were based on our previous
studies showing that at the chosen doses, all three
drugs produce a reliable and comparable disruption of
avoidance responding (Li et al. 2004; Li et al. 2009a,b;
Mead and Li 2009), and they give rise to clinical levels
of striatal D2 occupancy (50–80%) at these doses (Kapur et al. 2003). The doses of QUI and DOI were chosen based on our recent maternal behavior work showing that QUI 1.0 mg/kg was effective in reversing the
HAL-induced disruptions of active maternal behaviors
and that DOI 2.5 mg/kg was effective in reversing the
CLZ-induced disruptions of maternal behaviors (Zhao
and Li 2009). Previous work also showed that DOI produces maximal behavioral effects between 2 and 3 mg/
kg (Granoff and Ashby 1998; Halberstadt et al. 2009;
Schreiber et al. 1995).
Experiment 1: Effects of QUI pretreatment on
HAL- and CLZ-induced avoidance disruption
Sixty rats were first habituated to the two-way CAR
boxes for 2 days (20 min/day). Then, they were trained
for conditioned avoidance responding for ten sessions
over a 2-week period. Each session consisted of 30 trials. Every trial started by presenting the white noise
(CS) for 10 s, followed by a continuous scrambled footshock (0.8 mA, US, maximum duration = 5 s) on the grid
floor. If a subject moved from one compartment into the
other within the 10 s of CS presentation, it avoided the
shock and this shuttling response was recorded as avoidance. If the rat remained in the same compartment for
more than 10 s and made a crossing upon receiving the
footshock, this response was recorded as escape. If the
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rat did not respond during the entire 5 s presentation of
the shock, the trial was terminated and escape failure was
recorded. Intertrial intervals varied randomly between
30 and 60 s. The number of avoidance responses was
recorded.
At the end of the training session, 46 rats reached the
training criterion (>70% avoidance in each of the last
two sessions. Their averaged number of avoidances on
the last training day (mean) = 29.17, SE = 0.18). They
were first matched on avoidance performance on the
last training day (i.e., predrug) to create blocks of rats
(n = 5–6 rats/block) that were approximately equal in
performance. Within each block, they were then randomly assigned to one of five groups: VEH + VEH
(n = 10, saline + sterile water), VEH + HAL (n = 9),
VEH + CLZ (n = 9), QUI + HAL (n = 9), and QUI + CLZ
(n = 9), and repeatedly tested daily under the CS-only
(no shock, 30 trials/session) condition for three consecutive days. The CS-only condition was used to control the possible confound of number of shocks received
and to exclude any possible relearning effect caused
by the presence of the US. During each test, rats were
first pretreated with QUI 1.0 mg/kg (sc) or saline followed by an injection of sterile water, HAL 0.05 mg/
kg (sc) or CLZ 10.0 mg/kg (sc) 10 min later. Thirty minutes after the second injection, rats were placed in the
CAR boxes and tested. One day after the end of the 3rd
test, all rats were tested drug-free for one session under the CS-only (no shock) condition and retrained for
one session under the CS–US condition to bring their
avoidance back to the predrug level. A final drug challenge test was conducted 24 h after the retraining session to assess the long-term effect of repeated antipsychotic treatment on avoidance. During the test, rats in
the VEH + HAL and QUI + HAL groups were injected
with HAL 0.025 mg/kg, whereas rats in the VEH + CLZ
and QUI + CLZ groups were injected with CLZ 5.0 mg/
kg. Half of the VEH + VEH rats (n = 5) were injected
with HAL 0.025 mg/kg and another half (n = 5) were injected with CLZ 5.0 mg/kg. The CS-only test (no US, 30
trials) was conducted 30 min after the drug injection.

Experiment 2: Effects of DOI pretreatment on
HAL- and CLZ-induced avoidance disruption
The basic procedure was identical to that of experiment 1 with the exception that DOI (2.5 mg/kg, sc) pretreatment effect was examined. Sixty rats were used, of
which 45 reached the training criterion (>70% avoidance in each of the last two sessions, mean = 29.16,
SE = 0.23). Following the group assigning procedure as
described in experiment 1, they were allocated to the
following five groups: VEH + VEH (saline + sterile water), VEH + HAL (0.05 mg/kg), VEH + CLZ (10.0 mg/
kg), DOI + HAL, and DOI + CLZ, and were subjected to
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three sessions of drug testing and two sessions of drugfree testing/retraining and a final drug challenge test,
following the exact same schedule as described in experiment 1. During the challenge test, four VEH + VEH
rats were injected with HAL 0.025 mg/kg and five were
injected with CLZ 5.0 mg/kg.
Experiment 3: Effects of QUI and DOI pretreatment on
HAL and CLZ suppressive effect on motor activity in
the CAR
This experiment was designed to examine the specificity of the pretreatment effects of QUI and DOI on antipsychotic-induced avoidance disruption. We asked
whether the reversal effects could be attributed to the
drug’s effects on motor activity. The basic procedure
was similar to that used in the above experiments except that on the three drug days, rats were only tested
for their motor activity in the CAR boxes, not for their
avoidances (i.e., no CS or US was presented). Forty-eight
rats were trained in ten sessions, of which 34 reached
learning criterion (mean = 27.88, SE = 0.41). Following
the group assigning procedure as described in experiment 1, they were allocated to the following five groups:
VEH + VEH (n = 10, saline + sterile water), VEH + HAL
(n = 6), QUI + HAL (n = 6), VEH + CLZ (n = 6), and
DOI + CLZ (n = 6). Over the next 3 days, 30 min after
the second injection, they were placed in the CAR boxes
and motor activity was recorded for 30 min (the approximate time required to complete one CAR session). The
number of crossings between two compartments was
also recorded.
Experiment 4: effects of QUI and DOI pretreatment on
OLZ-induced avoidance disruption
This experiment examined the receptor mechanisms of acute and repeated effects of OLZ. The basic
procedure was identical to that of experiments 1 and
2 with the exception that both QUI (1.0 mg/kg) and
DOI (2.5 mg/kg) pretreatment effects were examined
against OLZ (1.0 mg/kg, sc). Sixty rats were trained in
ten sessions, of which 42 reached the training criterion
(mean = 28.60, SE = 0.31). Following the group assigning
procedure as described in experiment 1, they were allocated to the following five groups: VEH + VEH (n = 8,
saline + sterile water), VEH + OLZ (n = 9), QUI + OLZ
(n = 8), DOI + OLZ (n = 8), and QUI + DOI + OLZ (n
= 9), and were subjected to the three sessions of drug
testing and two sessions of drug-free testing/retraining
and a final drug challenge test. During the three drug
testing sessions, rats in the QUI + DOI + OLZ group
were injected with QUI and DOI first, followed by an injection of OLZ 10 min later. During the drug challenge
test, all rats were injected with OLZ at 0.5 mg/kg.
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Statistical analysis
The number of avoidance responses and motor activity data (number of photobeam breaks) were expressed
as mean ± SEM. Data on the three drug test sessions
were analyzed using a split-plot analysis of variance
(ANOVA) with the between-subjects factor being drug
group and the within-subjects factor being test session. To identify group difference on a specific test day,
one-way ANOVAs followed by post-hoc Tukey’s HSD
tests (for more than three groups) were used. Independent samples t tests were used to examine two-group
difference in cases where there was a prior research
hypothesis.
Results
Experiment 1: Effects of QUI pretreatment on HAL- and
CLZ-induced avoidance disruption
One rat from the QUI + CLZ group died unexpectedly before the retraining and drug challenge test. Its
data on these two sessions were not analyzed. As can
be seen in Figure 1, HAL and CLZ suppressed avoidance responding on the first drug day and maintained
this suppression over the 3 days in comparison to
the vehicle treatment. A split-plot ANOVA revealed
a main effect of drug treatment (F(4,41) = 50.271,
P < 0.001) and a significant treatment × session interaction (F(8,82) = 4.626, P < 0.001), but no significant main
effect of session (F(2,82) = 2.350, P = 0.102). One-way
ANOVAs followed by post-hoc tests on each drug test
day revealed that all drug groups differed significantly
from the VEH + VEH group (P < 0.001). Post-hoc analysis showed that on the 1st drug day, the QUI + HAL
group made significantly more avoidances than the
VEH + HAL group (P = 0.021), whereas the QUI + CLZ
group did not differ significantly from the VEH + CLZ
group (P = 0.991), suggesting that pretreatment of
QUI attenuated the HAL-induced disruption of avoidance responding on the 1st day, but did not affect the
CLZ-induced disruption. This attenuation effect was
no longer present on the subsequent two drug days (all
P > 0.10).
To detail the time course of the attenuation effect of
QUI, we examined the within-session change of avoidance responding across the three ten-trial blocks on
day 1 (data not shown). QUI completely reversed the
effect of HAL in the 1st block, but lost its effect in the
latter blocks (1st block, VEH + VEH vs. QUI + HAL,
P = 0.611; QUI + HAL vs. VEH + HAL, P = 0.010. Second and third blocks, VEH + VEH vs. QUI + HAL,
P > 0.13), a finding consistent with QUI’s relatively
short duration of action (Whitaker and Lindstrom
1987).
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Figure 1. Effects of pretreatment
of quinpirole on acute haloperidol and clozapine-induced avoidance disruption. Data are mean
(+SEM) numbers of avoidance
responses of the five groups of
rats on the last CAR training day
(predrug), three drug test days
(days 1 to 3) and two drug-free
test days (drug-free CS-only and
drug-free retraining). *P < 0.05
significantly different from the
VEH + VEH group; #P < 0.05
significantly different from the
VEH + HAL group.

HAL- and CLZ-treated rats reinstated their avoidance responding in just two sessions when the drug
treatments were stopped to a level that was comparable to that of vehicle treatment (Figure 1). On the drug
challenge test (Figure 2), rats previously treated with
HAL (i.e., VEH + HAL and QUI + HAL) showed much
lower avoidance responding than the vehicle rats treated
with HAL for the first time. However, an opposite pattern was observed in the CLZ challenge condition: the
CLZ-experienced rats (i.e., VEH + CLZ and QUI + CLZ)
showed much higher avoidance responding than the vehicle rat treated with CLZ for the first time. One-way
ANOVA revealed that under the HAL (0.025 mg/kg)
challenge condition, there was a main effect of group
(F(2,20) = 3.638, P = 0.045), and post-hoc tests showed
that the VEH + HAL rats made significantly fewer
avoidances than the VEH + VEH ones (HAL-challenged) (P = 0.039). The QUI + HAL group did not differ from the VEH + VEH (P = 0.116) nor the VEH + HAL
(P = 0.795). Under the CLZ (5.0 mg/kg) challenge condition, there was a main effect of group (F(2,19) = 6.837, P
= 0.006), and post-hoc tests showed that the QUI + CLZ
group made significantly more avoidances than the
VEH + VEH (CLZ-challenged) group (P = 0.005), but
not significantly more than the VEH + CLZ group
(P = 0.286).
Figure 2. Effects of pretreatment of quinpirole
on repeated effect of haloperidol and clozapine
treatment on avoidance responding. Data are
mean (+SEM) numbers of avoidance responses
on the challenge test day. Rats that were previously treated with either double vehicles
(n = 5), vehicle plus haloperidol (0.05 mg/kg),
or quinpirole (1.0 mg/kg) plus haloperidol
(0.05 mg/kg) were challenged with haloperidol (0.025 mg/kg). Rats that were previously
treated with either double vehicles (n = 5), vehicle plus clozapine (10.0 mg/kg), or quinpirole (1.0 mg/kg) plus clozapine (10.0 mg/
kg) were challenged with clozapine (5.0 mg/
kg). *P < 0.05 significantly different from the
corresponding VEH + VEH group.

Experiment 2: Effects of DOI pretreatment on HAL- and
CLZ-induced avoidance disruption
Once again, HAL and CLZ suppressed avoidance responding throughout the drug test period (Figure 3). A
split-plot ANOVA revealed a main effect of drug treatment (F(4, 40) = 48.301, P < 0.001). One-way ANOVAs
showed that all drug groups made significantly fewer
avoidances than the VEH + VEH group on every drug
test day (P < 0.001). Importantly, the DOI + CLZ group
made significantly more avoidance than the VEH + CLZ
group (day 1, P < 0.001; day 2, P = 0.005; and day 3,
P < 0.001), whereas the DOI + HAL group did not differ significantly from the VEH + HAL group (day 1,
P = 0.964; day 2, P = 0.738; and day 3, P = 1.000), suggesting that pretreatment of DOI attenuated the CLZ-induced disruption of avoidance responding, but did not
affect the HAL-induced disruption. This attenuation effect was persistent throughout the drug testing days.
The within-session pattern of avoidance responding
on the 1st drug day revealed that DOI pretreatment attenuated the avoidance disruptive effect of CLZ (not
HAL) in the 1st and 2nd 10-trial blocks (Tukey’s HSD
post-hoc test: DOI + CLZ vs. VEH + CLZ: P < 0.001
and P = 0.001, respectively), but lost its effect in the last
block (P = 0.195) (data not shown). A similar pattern
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Figure 3. Effects of pretreatment
of DOI on acute haloperidol
and clozapine-induced avoidance disruption. Data are mean
(+SEM) numbers of avoidance
responses of the five groups of
rats on the last CAR training day
(predrug), three drug test days
(days 1 to 3) and two drug-free
test days (drug-free CS-only and
drug-free retraining). * < 0.05
significantly different from the
VEH + VEH group; #P < 0.05
significantly different from the
VEH + CLZ group.

was found on the 2nd and 3rd drug days with a significant reversal occurring in the 1st and 2nd blocks.
On the drug challenge test (Figure 4), rats previously
treated with HAL (i.e., the VEH + HAL rats) made fewer
avoidance responses than the vehicle rats treated with
HAL for the 1st time, indicating a sensitization-like HAL
effect. One-way ANOVA revealed that under the HAL
(0.025 mg/kg) challenge condition, there was a main effect of group (F(2,21) = 5.122, P = 0.017). Post-hoc tests
indicated that the VEH + VEH and DOI + HAL groups
did not differ from each other (P = 0.904), but made significantly more avoidances than the VEH + HAL group
(P = 0.046 and 0.033, respectively), indicating that pretreatment of DOI attenuated the long-term repeated HAL
effect. Under the CLZ (5.0 mg/kg) challenge condition,
the prior CLZ-treated rats tended to make more avoidances than the vehicle rats treated with CLZ for the 1st
time, although the overall effect failed to reach a signif-

icant level (F(2,22) = 2.103, P = 0.148). Pretreatment of
DOI failed to change the long-term repeated CLZ effect
(with there being no significant difference between the
VEH + CLZ and DOI + CLZ, P > 0.72).
Results from the above experiments suggest that pretreatment of DOI, but not QUI, attenuated the long-term
repeated HAL effect on avoidance, whereas pretreatment of QUI, but not DOI, potentiated the long-term repeated CLZ effect. To examine whether this conclusion
holds if data from both experiments were combined, we
conducted two separate one-way ANOVAs for the combined HAL groups (i.e., VEH + VEH challenged with
HAL, VEH + HAL, QUI + HAL, and DOI + HAL) and
the combined CLZ groups (i.e., VEH + VEH challenged
with CLZ, VEH + CLZ, QUI + CLZ, and DOI + CLZ).
Results were consistent with the analyses presented
above (Figure 5). Under the HAL challenge condition, the VEH + HAL group made significantly fewer

Figure 4. Effects of pretreatment of DOI on repeated effect of haloperidol and clozapine treatment on avoidance responding. Data
are mean (+SEM) numbers of avoidance responses on the challenge test day. Rats that were previously treated with either double
vehicles (n = 4), vehicle plus haloperidol (0.05 mg/kg), or DOI (2.5 mg/kg) plus haloperidol (0.05 mg/kg) were challenged with
haloperidol (0.025 mg/kg). Rats that were previously treated with either double vehicles (n = 5), vehicle plus clozapine (10.0 mg/
kg), or DOI (2.5 mg/kg) plus clozapine (10.0 mg/kg) were challenged with clozapine (5.0 mg/kg). *P < 0.05 significantly different
from the corresponding VEH + VEH group; #P < 0.05 significantly different from the VEH + HAL group.
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Figure 5. Combined effects of
pretreatment of quinpirole and
DOI on repeated effect of haloperidol and clozapine treatment on avoidance responding.
Data are mean (+SEM) numbers
of avoidance responses on the
drug challenge test of the eight
groups of rats combined from
Experiment 1 and 2. *P < 0.05
significantly different from the
corresponding VEH + VEH
group; #P < 0.05 significantly
different from the VEH + HAL
group.

avoidances than the VEH + VEH group (Tukey’s HSD,
P = 0.003), and the DOI + HAL group made significantly more avoidances than the VEH + HAL group
(P = 0.027). Under the CLZ condition, the VEH + VEH
group did not differ significantly from the VEH + CLZ
group (P = 0.103), but did make significantly fewer
avoidances than the QUI + CLZ group (P = 0.003).

(P < 0.05). Also, the QUI + HAL group made significantly more crossings than the VEH + HAL group on
day 1 (P = 0.038), but not on day 2 (P = 0.454) or three
(P = 0.332). The DOI + CLZ group made significantly
more crossings than the VEH + CLZ group only on
day 2 (P = 0.003), but not on day 1 (P = 0.235) and day 3
(P = 0.245).

Experiment 3: Effects of QUI and DOI pretreatment
on HAL and CLZ suppressive effect on motor
activity in the CAR

Experiment 4: Effects of QUI and DOI pretreatment on
OLZ-induced avoidance disruption

Both HAL and CLZ suppressed motor activity and
inter-compartment crossings of well-trained rats in the
CAR boxes. Pretreatment of QUI and DOI exhibited a
strong attenuation effect on HAL and CLZ, respectively
(Figure 6a, b). On the motor activity, a split-plot ANOVA
revealed a main effect of group (F(4,29) = 53.053,
P < 0.001), session (F(2,58) = 13.525, P < 0.001), and
group × session interaction (F(8,58) = 4.754, P < 0.001).
Individual one-way ANOVA on each drug day showed
a main effect of group (P < 0.001). Post-hoc tests indicated that all drug groups were less active than the
VEH + VEH group on the drug test days (all P < 0.001)
except on day 1, when the QUI + HAL group did
not differ significantly from the VEH + VEH group
(P = 0.338). In addition, the QUI + HAL group was significantly more active than the VEH + HAL group
on day 1 (P = 0.005) and day 3 (P = 0.029), but not on
day 2 (P = 0.385). The DOI + CLZ group was significantly more active than the VEH + CLZ group only on
day 2 (P = 0.003), but not on days 1 (P = 0.289) and 3
(P = 0.177).
On the number of crossings, a split-plot ANOVA
revealed a main effect of group (F(4,29) = 16.797,
P < 0.001), session (F(2,58) = 13.642, P < 0.001), and
group × session interaction (F(8,58) = 3.738, P = 0.001).
Individual one-way ANOVA on each drug day showed
a main effect of group (P < 0.001) with the VEH + HAL
and VEH + CLZ groups showing significantly fewer
crossings than the VEH + VEH group on every test day

OLZ 1.0 mg/kg suppressed avoidance responding on the first drug day and progressively enhanced
its suppression over the 3-day period (Figure 7). A
split-plot ANOVA revealed a main effect of OLZ
(F(4,37) = 11.154, P < 0.001), a main effect of session
(F(2,74) = 8.558, P < 0.001), but no OLZ × session interaction (F(8,74) = 0.943, P = 0.487). Individual one-way
ANOVA showed that the drug groups made significantly fewer avoidances than the VEH + VEH group on
each drug day (P = 0.035–0.001) except on day 1, when
the QUI + OLZ group (P = 0.262) and the DOI + OLZ
group (P = 0.053) were not significantly different from
the VEH + VEH group.
The analysis of within-session patterns of avoidance responding on drug days 1 and 2 revealed that the
VEH + OLZ group made significantly fewer avoidances
than the VEH + VEH group in every block on both days
(P < 0.034). In contrast, the QUI + OLZ group was only
significantly different from the VEH + VEH group in
the last block on day 2 (P = 0.033). Furthermore, the
QUI + OLZ group also made more avoidances than the
VEH + OLZ group in the 2nd block on day 2 (P = 0.019),
suggesting that pretreatment of QUI significantly attenuated the avoidance disruptive effect of OLZ.
On the drug challenge test (Figure 8), rats previously treated with VEH + OLZ made fewer avoidances than the VEH + VEH rats. Independent samples t tests showed a significant group difference
between the VEH + VEH and VEH + OLZ groups
(t(15) = 2.524, P = 0.023), a finding consistent with our
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Figure 6. Effects of pretreatment of quinpirole and DOI
on haloperidol and clozapine-induced motor suppression without CAR test. a) Motor activity (mean number of
photobeam breaks), and b)
mean number of crossings of
the five groups of rats on the
last CAR training day (predrug), three drug test days
(days 1 to 3), and two drugfree test days (drug-free CSonly and drug-free retraining). They were either treated
subcutaneously with double vehicles, vehicle plus haloperidol (0.05 mg/kg), or
clozapine (10.0 mg/kg), or
quinpirole (1.0 mg/kg) plus
haloperidol (0.05 mg/kg), or
DOI (2.5 mg/kg) plus clozapine (10.0 mg/kg). *P < 0.05
significantly different from
the VEH + VEH group;
#P < 0.05 significantly different from the VEH + HAL or
VEH + CLZ group.

previous work (Li et al. 2009a; Mead and Li 2009). Both
QUI and DOI pretreatment attenuated the long-term
repeated OLZ effect. However, overall group difference was only marginally significant (overall group
difference: F(4,41) = 2.258, P = 0.081). To further examine the pretreatment effect of QUI and DOI, we anFigure 7. Effects of pretreatment of quinpirole and DOI
on acute olanzapine-induced
avoidance disruption. Data
are mean (+SEM) numbers of
avoidance responses of the
five groups of rats on the last
CAR training day (predrug),
three drug test days (days 1 to
3), and two drug-free test days
(drug-free CS-only and drugfree retraining). *P < 0.05 significantly different from the
VEH + VEH group.

alyzed the within-session pattern of avoidance responding on the drug memory test day (data not
shown). The only significant group differences were
noted between the VEH + OLZ group and one of the
two QUI pretreated groups in the 2nd block (oneway ANOVA: F(4,41) = 3.204, P = 0.023; Tukey’s
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Figure 8. Effects of pretreatment
of quinpirole and DOI on repeated
effect of olanzapine treatment on
avoidance responding. Data are
mean (+SEM) numbers of avoidance responses on the drug challenge test. *P < 0.05 significantly
different from the VEH + VEH
group based on the independent
samples t test.

HSD post hoc: P = 0.042 vs. QUI + OLZ; P = 0.036 vs.
QUI + DOI + OLZ), but not to the DOI pretreated group
(P = 0.095), suggesting that QUI pretreatment is more
efficacious than DOI in attenuating the long-term repeated OLZ effect.
Discussion
The present study demonstrates interesting dissociated dopamine and serotonin receptor mechanisms underlying acute and repeated effects of HAL, CLZ, and
OLZ on avoidance responding—a validated behavioral measure of antipsychotic efficacy (Wadenberg and
Hicks 1999). Table 1 summarizes the possible receptor
mechanisms as identified in the present study.
HAL is a typical antipsychotic with strong dopamine
D2 receptor antagonism and low 5-HT2A/2C antagonism
(Miyamoto et al. 2005). It is not surprising to see that
QUI, a dopamine D2/3 agonist, but not DOI, a mixed
5-TH2A/2C agonist, was able to reverse the avoidance
disruptive effect of HAL (a simple agonist–antagonist
interaction). This finding confirms that HAL disrupts
avoidance responding primarily by blocking D2 receptors (Wadenberg et al. 2001b) and is consistent with previous work showing that compounds (e.g., l-dopa) that
increase endogenous dopamine activity can reverse antipsychotic-induced disruption of avoidance responding (Davies and Redfern 1974; Seiden and Hanson 1964;
Seiden and Peterson 1968). It is also in agreement with
other findings showing that QUI and HAL counteract each other in a variety of behavioral tasks, e.g., cat-

alepsy (Ninan and Kulkarni 1999), prepulse inhibition
(Caine et al. 1995; Wan and Swerdlow 1993), and psychogenic polydipsia (Amato et al. 2008).
CLZ and OLZ are potent 5-HT2A/2C receptor antagonists and relatively weaker dopamine D2 antagonists
(Meltzer et al. 2003; Meltzer et al. 1989), but to what extent each receptor action contributes to their disruptive effect on avoidance responding has not been studied. For OLZ, previous studies suggest that blockade
of dopamine D2 receptors in the striatum is an integral
component (Olsen et al. 2008; Wadenberg et al. 2001b).
Our finding that QUI attenuated the disruptive effect of
OLZ is consistent with those studies. However, whether
OLZ’s antagonist action on 5-HT2A/2C receptors also
contributes to its avoidance disruption is not known.
Based on the evidence that adjunct treatment with selective 5-HT2A receptor antagonists to low doses of dopamine D2 blocking compounds, enhances the antipsychotic-like suppression of CAR in rats (Wadenberg et al.
1996), we can assume that OLZ’s 5-HT2A receptor antagonism may contribute to its disruption on CAR. Given
that 5-HT2C agonism is known to exert an antipsychoticlike suppression on CAR (Wadenberg and Hicks 1999),
we speculate that OLZ’s antagonism on 5-HT2C receptors may actually lessen its disruptive effect on CAR via
D2 and 5-HT2A antagonism mechanisms. Therefore, the
lack of DOI reversal effect on OLZ could be explained
by DOI’s agonist action on 5-HT2C which may have
masked its reversal effect on OLZ via 5-HT2A receptors. Thus, in the case of OLZ, it appears that its avoidance disruptive effect is mainly mediated by its D2 and
5-HT2A antagonism. Its 5-HT2C antagonism may possi-

Table 1. Possible receptor mechanisms underlying acute and repeated effect of haloperidol, clozapine, and olanzapine treatment
Antipsychotic drugs

Haloperidol

Clozapine

Olanzapine

Acute effect
Repeated effect

D2
5-HT2A/2C

5-HT2A/2C
D2

D2
D2 and 5-HT2A/2C (to a lesser extent)
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bly lessen its avoidance effect. This notion is also consistent with other evidence showing that 5-HT2C antagonism is functionally opposed to 5-HT2A antagonism
with regard to antipsychotic action (Meltzer 2002). More
work employing more selective 5-HT2A and 5-HT2C is
needed validate this conclusion.
Based on their receptor binding profiles (Miyamoto
et al. 2005) as well as findings from our maternal behavior work (Zhao and Li 2009), we hypothesized that
pretreatment of DOI, but not QUI would attenuate
acute CLZ-induced disruption on avoidance responding. Results confirm this hypothesis. The lack of an effect of QUI on the acute effect of CLZ is similar to what
we observed in our maternal behavior study (Zhao and
Li 2009), and suggests that its D2 antagonism may not
play an important role in its acute effect on avoidance
responding. This conclusion is consistent with the observation that although CLZ at 10.0 mg/kg causes 50%
inhibition of avoidance responding, it only produces
25% dopamine D2 receptor occupancy (Olsen et al.
2008), far less than what is required to achieve its clinical effect (Kapur et al. 2000). Others also reported that
DOI at 10 mg/kg reversed the avoidance disruptive effect of 10 mg/kg CLZ (Browning et al. 2005), suggesting the reversal effect of DOI on CLZ is quite robust and
is a generalized effect. Because CLZ has dual action on
both 5-HT2A and 5-HT2C receptors, and DOI is nonselective for 5-HT2A versus 5-HT2C receptors, it is impossible
to determine which exact receptor action is responsible
for DOI’s reversal effect and CLZ’s avoidance disruptive effect. There are good reasons to speculate that CLZ
may disrupt avoidance responding by primarily antagonizing 5-HT2A receptor, as opposed to 5-HT2C. Firstly,
5-HT2C receptor agonists (e.g., WAY-163909, mCPP, DLSD) are shown to possess a property of suppressing
avoidance responding (Grauer et al. 2009; Wadenberg
and Hicks 1999). If DOI works by antagonizing CLZ-induced blockade of 5-HT2C receptors, we would expect
pretreatment of DOI to potentiate the disruptive of CLZ,
as opposed to reverse it. Secondly, selective 5-HT2C receptor agonists are generally ineffective in counteracting CLZ. For example, Ro 60-0175 (3 mg/kg), a selective 5-HT2C receptor agonist is incapable of attenuating
CLZ (20 mg/kg)—induced dopamine release in rat medial prefrontal cortex, whereas DOI (2.5 mg/kg) is capable of achieving such an effect (Ichikawa et al. 2001).
Thirdly, many behavioral and molecular effects of DOI
are found to be mediated by its antagonism on 5-HT2A
receptors, not on 5-HT2C receptors. For example, DOIinduced effects on locomotor activity, drug discrimination, head-twitch response, and prepulse inhibition
(PPI) of acoustic startle are antagonized by 5-HT2A-selective antagonist (e.g., M100907) but not by selective
5-HT2C/2B antagonists (e.g. SB 200,646A, SB 206,553, and
SER-082) (Halberstadt et al. 2009; Schreiber et al. 1995;
Sipes and Geyer 1995, 1997; Smith et al. 2003), and re-
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peated DOI administration induces significant changes
in binding in 5-HT2A receptors but not 5-HT2C receptors
(Smith et al. 1999).
At the behavioral level, we observed that the patterns
of reversal effects of QUI and DOI are fairly consistent
with their reversal effects on HAL- and CLZ-induced motor suppression (Figure 6). It is thus tempting to suggest
that QUI and DOI attenuated HAL- and CLZ-induced
avoidance disruption by increasing motor function. This
view may be too simplistic because the increased motor activity and number of inter-compartment crossings
may reflect other psychological processes, such as an increase in arousal and attention, or an increase in motivation in responding to stimuli. The motor function view
is also difficult in explaining why QUI failed to attenuate the effect of CLZ and DOI failed to attenuate the effects of HAL, as well as why the combination of QUI and
DOI also failed to attenuate the effect of OLZ. It is also incompatible with the findings that DOI at this dose range
decreases, not increases, motor activity in rats (Elliott et
al. 1990; Granoff and Ashby 1998; Hawkins et al. 2008;
Hillegaart et al. 1996; Krebs-Thomson and Geyer 1996)
and that pretreatment of DOI can reduce neuroleptic-induced catalepsy (presumably increasing motor function)
(Wadenberg and Ahlenius 1995). The additional finding
that QUI at 1.0 mg/kg had little effect on avoidance responding by itself, whereas DOI at 2.5 mg/kg actually
suppressed avoidance (see Table 2) is also inconsistent
with the general motor function view.
In our previous studies and the present one, we have
observed that rats that have been previously treated
with HAL and OLZ make significantly fewer avoidance
responses than rats treated with these drugs for the first
time in a later drug challenge test (Li et al. 2007, 2009a;
Mead and Li 2009). Interestingly, CLZ appeared to produce an opposite effect: rats previously treated with
CLZ tended to make more avoidances than CLZ-naïve
rats. This tolerance-like effect of CLZ is not new (Goudie
Table 2. The effect of QUI and DOI treatment alone on avoidance responding
 	

Predrug

Testa

QUI-1.0 mg/kg (n = 12)
DOI-2.5 mg/kg (n = 15)

27.64 ± 0.897
28.07 ± 0.679

22.64 ± 3.082
8.73 ± 2.205*

Rats from experiment 3 were first retrained in a 30-trial CAR
session to reacquire avoidance responding. Only those that
reached the retraining criterion (>70% avoidance responses)
in that retraining session were used in this follow-up test.
Rats tested with QUI-1.0 mg/kg consisted of rats that were
treated with either vehicle, HAL or QUI + HAL in experiment 3. Rats tested with DOI-2.5 mg/kg consisted of rats
that were treated with vehicle, CLZ or DOI + CLZ in experiment 3.
* P < 0.001 significantly different from the predrug condition
a. QUI (1.0 mg/kg, s) and DOI (2.5 mg/kg, s) were administered 40 min before a 30-trial CAR test
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et al. 2007a, b; Villanueva and Porter 1993), as Sanger
(1985) also reported that tolerance developed rapidly
to the avoidance disruptive effect of CLZ with repeated
administration over 4 days. The new findings are on the
distinct receptor mechanisms behind the sensitization
and tolerance-like effects. Our results indicate that the
repeated effect of HAL may be mediated by its action on
5-HT2A/2C receptor system, whereas the repeated effect
of OLZ and CLZ may be mediated by their action on
D2/3 receptor system. Given the fact that HAL is also a
5-HT2A receptor inverse agonist (Weiner et al. 2001), and
repeated HAL treatment causes a reduction in 5-HT2A
receptor mRNA expression in various limbic regions
(Buckland et al. 1997), it is possible that HAL causes a
sensitization-like effect in this model by down-regulating 5-HT2A receptor. DOI may decrease this long-term
impact of HAL by counteracting its effect on 5-HT2A receptor. This idea is also consistent with the well-known
augmentation effect of 5-HT2A antagonism on HAL. For
example, 5-HT2A-selective antagonist M100907 is shown
to potentiate HAL-induced dopamine release in the medial prefrontal cortex (Bonaccorso et al. 2002), to reduce
the reward-attenuating effect of HAL (Benaliouad et al.
2007), and to potentiate the avoidance disruptive effect
of HAL (Wadenberg et al. 2001a). The repeated effect of
CLZ and OLZ via D2/3 receptor systems could be understood in the context of their known long-term effect on
D2/3 receptors (Atkins et al. 1999; Kapur et al. 2003; Moran-Gates et al. 2006). One important task for future research is to figure out how antipsychotics induce brain
changes through these and other receptor systems (e.g.,
5-HT1A, D1, D4, etc.) and how important different receptor mechanisms are to the clinical antipsychotic action
of a drug.
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